07:37 AM EDT, 06/27/2025 (MT Newswires) -- Tango Therapeutics ( TNGX ) said Friday that the first patient has been dosed in a phase 1/2 trial of TNG462 in combination with Revolution Medicines' ( RVMD ) daraxonrasib or zoldonrasib in certain pancreatic and lung cancer patients.

The trial is evaluating safety, pharmacokinetics, pharmacodynamics and antitumor activity of TNG462 in a combination therapy.

TNG462 is also being evaluated as a monotherapy in another phase 1/2 trial, with data expected in H2 of 2025, Tango said.